check_circleStudy Completed

Neoplasms

Japanese BAY1000394 monotherapy Phase I study

Trial purpose

This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.

Key Participants Requirements

Sex

Both

Age

20 - N/A

Trial summary

Enrollment Goal
12
Trial Dates
May 2014 - July 2018
Phase
Phase 1
Could I Receive a placebo
No
Products
Roniciclib (BAY1000394)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Kashiwa, 277-8577, Japan
Completed
Fukuoka, 811-1395, Japan

Primary Outcome

  • Number of participants with adverse events as a measure of safety and tolerability
    date_rangeTime Frame:
    6 months
    enhanced_encryption
    Safety Issue:
    Yes
  • Number of participants with abnormal lab parameters based on descriptive statistics
    date_rangeTime Frame:
    6 months
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum observed drug concentration (Cmax) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
    enhanced_encryption
    Safety Issue:
    No
  • Cmax divided by dose per body weight (Cmax,norm) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
    enhanced_encryption
    Safety Issue:
    No
  • Cmax divided by dose (Cmax/D) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • Area under the concentration versus time curve from zero to infinity after single dose (AUC) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    = Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)
  • AUC from time 0 to 12 hours after single dose (AUC(0-12) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8 and 12 hours
  • AUC divided by dose per body weight (AUCnorm) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)
  • AUCnorm from time 0 to 12 hours after single dose (AUC(0-12),norm) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8 and 12 hours
  • AUC divided by dose (AUC/D) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose)
  • Time to reach Cmax (tmax) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • Terminal half-life (t½) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • Maximum observed drug concentration after multiple dosing (Cmax,md) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • Cmax divided by dose per body weight after multiple dosing (Cmax,norm,md) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • Cmax divided by dose (Cmax,md/D) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • AUC from time 0 to 12 hours after multiple dosing (AUC(0-12),md) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • AUCnorm from time 0 to 12 hours after multiple dosing (AUC(0-12),norm,md) for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)
  • AUC from time 0 to 12 hours divided by dose after multiple dosing for BAY1000394 and its metabolite M-1
    date_rangeTime Frame:
    Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)

Secondary Outcome

  • Tumor response
    date_rangeTime Frame:
    Screening and on Day 21 of even numbered cycle
    enhanced_encryption
    Safety Issue:
    No

Trial design

An open-label, Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1